www射-国产免费一级-欧美福利-亚洲成人福利-成人一区在线观看-亚州成人

BIZCHINA> Top Biz News
Profits up for flu vaccine makers
By Ding Qingfen (China Daily)
Updated: 2009-11-16 07:55

Profits up for flu vaccine makers

Primary school students receive injections of anti-H1N1 influenza medicine in Hunan province. GlaxoSmithKline (GSK) has received orders for 1.2 million packs of its anti-H1N1 influenza medicine, Relenza, from the Chinese government. [Asianewsphoto]

International pharmaceutical companies are cashing in on China's efforts to protect its people from the H1N1 pandemic with anti-influenza medicines.

GlaxoSmithKline (GSK), a leading international pharmaceutical company and China's largest by sales volume, received approval from the State Food and Drug Administration for its anti-H1N1 influenza medicine to enter the China market in July.

Since then, GSK has prepared 1.2 million packs of the anti-H1N1 influenza medicine called Relenza available for governments at all levels in China. The governments are storing the anti-virus in anticipation of a massive flu outbreak in coming months.

"GSK expects very strong demand for Relenza this year in China," Mark Reilly, general manager of GSK China, told China Business Weekly.

Profits up for flu vaccine makers

Chen Zhaorong, area medical manager at GSK China, also predicted that GSK will receive more orders in the months ahead.

"Compared with that from the other nations worldwide, China's orders are still small (for GSK)," Chen said.

Actually, the production capacity for Relenza is around 60 million packs. GSK has contracts in place to supply Relenza to over 60 economies. Of which, at least 10 percent of its new production have been allocated for developing nations.

But Chinese rules require that only governments can purchase the anti-H1N1 flu medicine. Relenza is still unavailable for sale to consumers.

As the weather turns colder, China is now bracing for a major H1N1 flu case outbreak. As of Nov 11, more than 62,871 cases were reported in 31 provinces, municipalities and autonomous regions of the Chinese mainland. About 32,000 cases were reported just since Oct 12.

Related readings:
Profits up for flu vaccine makers 8M+ Chinese inoculated with A(H1N1) flu vaccine
Profits up for flu vaccine makers Two died after inoculation of A(H1N1) flu vaccine
Profits up for flu vaccine makers Beijing to extend A(H1N1) flu vaccine inoculation
Profits up for flu vaccine makers H1N1 vaccine and common flu vaccine to merge

"Many regions are entering the traditional period for possible flu outbreaks, which will last for two to three months, and prevention and control work is becoming tougher," said Liang Wannian, vice director of the health emergency office under the Ministry of Health.

The Chinese government plans to allocate 1.09 billion yuan ($159.65 million) for prevention and treatment of the flu, including purchases of vaccinations, anti-viral medicines and medical instruments.

The huge investment is attracting global players like GSK. To meet the growing demand for anti-virals in China, GSK is considering investing in a manufacturing facility to produce Relenza for the country, said the GSK's Reilly, declining to elaborate.


(For more biz stories, please visit Industries)

   Previous page 1 2 Next Page  

主站蜘蛛池模板: 成人免费观看高清在线毛片 | 亚洲成a人片毛片在线 | 成人免费观看高清在线毛片 | 91热久久免费频精品动漫99 | 国产综合久久 | 亚洲一区二区三区视频 | 国产亚洲综合久久 | 国产亚洲高清在线精品不卡 | 精品丝袜国产自在线拍亚洲 | 欧美一级永久免费毛片在线 | 日韩一级片在线免费观看 | 久久久视频在线 | 欧美成人一级视频 | 国产欧美一区二区三区免费 | 欧美一区二区三区视频在线观看 | 日韩特黄特色大片免费视频 | 99久久精品免费精品国产 | 精品国产一区在线观看 | 亚洲一区日韩一区欧美一区a | 成人18免费视频 | 一个人看的www片免费视频中文 | 色www永久免费网站国产 | 免费观看欧美成人h | 日本波多野结衣在线 | 99国产在线播放 | 国产精品无码久久久久 | 免费又黄又爽的视频 | 亚洲欧美一区二区三区久本道 | 色悠久 | 国产成人午夜极速观看 | 亚洲日本一区二区三区高清在线 | 中文字幕成人网 | 日韩欧美亚洲国产 | 亚洲最大的视频网站 | 免费a级毛片大学生免费观看 | 午夜三级网 | 在线免费亚洲 | 欧美综合在线观看 | 免费在线观看一区 | 国产成人久久综合二区 | 国产亚洲精品久久久久久 |